StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Regeneron Pharma (REGN) PT Raised to $700 at Canaccord Genuity on $450M BARDA COVID-19 Grant
July 8, 2020 7:49 AM
Canaccord Genuity analyst John Newman raised the price target on Regeneron Pharma (NASDAQ: REGN) to $700.00 (from $660.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change